Does Tacrolimus Cause Cancer? Explaining the Risks

Tacrolimus can contribute to cancer development when taken as a systemic drug at the high doses used to prevent organ rejection after transplantation, but the topical ointment applied to skin for conditions like eczema carries little to no measurable cancer risk according to the best available evidence. That distinction is crucial, because the same drug name appears on both a transplant patient’s daily pill regimen and a tube of eczema cream, and conflating the two has fueled years of unnecessary worry among dermatology patients. The story gets more interesting once you look at the mechanisms, the dose-response data, and the controversy behind the FDA’s black box warning.

The Transplant Setting Is Where the Risk Lives

Organ transplant recipients take tacrolimus by mouth or intravenously, maintaining blood levels high enough to suppress the immune system around the clock. That sustained, whole-body immunosuppression is what keeps a donated kidney, liver, or heart from being attacked by the recipient’s own immune cells. It also, predictably, weakens the body’s ability to detect and destroy abnormal cells before they become tumors. Roughly one in eight solid-organ transplant recipients develops skin cancer, with squamous cell carcinoma accounting for the majority of cases.¹ Post-transplant lymphoproliferative disorder, a spectrum of abnormal lymphoid growths ranging from benign overgrowth to aggressive lymphoma, is another well-documented complication.

A single-center study of liver transplant recipients found that tacrolimus-based immunosuppression roughly doubled the risk of developing a new malignancy compared with cyclosporine-based regimens, after accounting for other risk factors like age and sex.² That finding needs context: cyclosporine is another calcineurin inhibitor, so neither option is risk-free. The question for transplant teams is usually which regimen offers the best balance of organ protection and long-term safety, not whether immunosuppression itself carries cancer risk. It does, across the board.

How Systemic Tacrolimus Promotes Tumors

The cancer risk from systemic tacrolimus is not a single-pathway problem. At least three mechanisms work together, and understanding them helps explain why higher doses and longer exposure translate to more tumors.

The most straightforward mechanism is reduced immune surveillance. Your immune system constantly patrols for cells that have accumulated mutations and begun dividing abnormally. Tacrolimus blocks a key step in T-cell activation, which is exactly why it prevents organ rejection, but the same T cells that would attack a transplanted organ also attack early-stage tumors. Suppress them long enough and some cancers slip through.

Beyond passive immune suppression, laboratory research shows tacrolimus can directly promote tumor cell survival and migration. In cell-culture experiments, tacrolimus enhanced the survival of squamous cell carcinoma cells in a dose-dependent manner and increased the ability of both normal and cancerous skin cells to migrate, a hallmark of invasive cancer behavior.³ This suggests the drug is not merely a passive bystander that allows tumors to grow unchecked; it may actively encourage their progression.

A third pathway involves viruses that cause cancer. Epstein-Barr virus (EBV), which most people carry without symptoms, is the main driver behind post-transplant lymphoproliferative disorder. Lab studies have shown that both tacrolimus and cyclosporine protect EBV-infected B cells from dying, allowing them to expand in ways that can eventually become lymphoma.⁴ In pediatric liver transplant recipients, higher blood tacrolimus levels have been linked to worse survival after developing post-transplant lymphoproliferative disorder, with levels above roughly 11 ng/mL being a particularly concerning threshold.⁵

Higher Cumulative Exposure Means Higher Risk

For transplant patients, tacrolimus is not an all-or-nothing risk. The cumulative amount of drug exposure over time matters. A recent analysis found that for every 20 percent increase in cumulative tacrolimus trough levels during the first year after transplant, the risk of developing any malignancy rose by about 9 percent. The relationship held beyond the first year as well. Patients whose average tacrolimus levels placed them in the highest quartile of exposure faced a 47 percent greater malignancy risk compared with those in the lowest quartile.⁶

This dose-response relationship is one reason transplant medicine has gradually moved toward lower tacrolimus targets over the decades. Early in the transplant era, blood levels were kept quite high, and cancer rates reflected that. A study of pediatric kidney transplant recipients found that in the late 1980s and early 1990s, tacrolimus use was strongly associated with post-transplant lymphoproliferative disorder. By the late 1990s, when dosing strategies had evolved and monitoring improved, that association had essentially disappeared.⁷ Better dosing does not eliminate the risk entirely, but it demonstrates that the risk is modifiable.

Topical Tacrolimus Barely Enters the Bloodstream

The eczema ointment version of tacrolimus sits at the opposite end of the exposure spectrum. When you apply tacrolimus cream to inflamed skin, only a tiny fraction reaches the blood. Pharmacokinetic studies in adults with moderate-to-severe atopic dermatitis found that about 94 to 96 percent of blood samples contained tacrolimus concentrations below 1 ng/mL, and roughly a quarter to a third of samples were below even the lowest measurable level.⁸ Blood levels after applying the ointment were hundreds of times lower than the concentrations found in the skin itself, indicating the drug stays overwhelmingly local.

Repeated application over two weeks did not cause tacrolimus to build up in the body. Peak blood concentrations remained low, and as the skin healed and the barrier function improved, absorption actually decreased further.⁹ To put this in perspective, transplant patients typically maintain blood tacrolimus levels somewhere between 5 and 15 ng/mL, depending on the phase of treatment. The topical ointment produces blood levels that are a fraction of a single nanogram per milliliter, orders of magnitude below what is needed for systemic immune suppression and far below what the dose-response data links to cancer.

What Large Studies Show About Topical Use and Cancer

Given how little tacrolimus actually reaches the bloodstream from the ointment, you would expect population-level cancer rates in topical users to be unremarkable. That is what the evidence broadly shows, though with a few wrinkles worth unpacking.

A systematic review and meta-analysis published in The Lancet Child and Adolescent Health pooled data from observational studies and randomized trials across all age groups. The absolute cancer risk with topical calcineurin inhibitor exposure was essentially the same as in controls: about 4.7 per 1,000 users versus 4.6 per 1,000 without exposure. The odds ratio for tacrolimus specifically was 0.99, meaning no detectable difference from the background cancer rate.¹⁰

A large study of adults with atopic dermatitis found no association between topical calcineurin inhibitor use and the risk of keratinocyte carcinomas (the most common skin cancers, including basal cell and squamous cell types). This held true regardless of the dose, frequency, or duration of use, and the result was consistent whether the comparison group was people using topical corticosteroids or people using neither treatment.¹¹

A pharmacovigilance study analyzing the FDA’s own adverse event reporting system from 2014 through 2025 also found no significant lymphoma safety signal associated with topical tacrolimus or pimecrolimus, including when the analysis was restricted specifically to patients using these drugs for atopic dermatitis.

The Lymphoma Question Is More Complicated

The one area where the topical data gives some researchers pause involves a specific subtype of lymphoma. The JOELLE study, a large European cohort that followed topical tacrolimus and pimecrolimus users for years, found that rates of most cancers in adult tacrolimus users were at or below those of people using topical corticosteroids. The exception was cutaneous T-cell lymphoma, where tacrolimus users had a rate ratio of 1.80 compared with corticosteroid users.¹²

Before reading too much into that number, there is a well-known confounding problem here. Cutaneous T-cell lymphoma in its early stages can look a lot like eczema. It causes red, scaly, itchy patches that respond partially to anti-inflammatory treatments. Patients who actually have early cutaneous T-cell lymphoma but are misdiagnosed with eczema would naturally end up in the tacrolimus user group, inflating the apparent association. The JOELLE study’s earlier analysis flagged the same pattern and acknowledged this diagnostic overlap as a likely contributor.¹³ A separate systematic review and meta-analysis did find a pooled 35 percent higher risk of lymphoma overall in topical calcineurin inhibitor users compared with topical corticosteroid users, but the authors similarly noted that the signal is difficult to separate from misclassification bias.¹⁴

In other words, the lymphoma signal in topical users probably reflects, at least partly, the reality that some people prescribed tacrolimus ointment for “eczema” never actually had eczema. Whether any residual real risk exists on top of that confounding effect remains genuinely uncertain, but even the unadjusted numbers involve a rare cancer, so the absolute risk difference is tiny.

The Black Box Warning and Why It Remains Controversial

In 2005, the FDA placed a black box warning on topical tacrolimus ointment and pimecrolimus cream, its most serious safety label. The warning cited the lack of long-term safety data at the time and a theoretical risk of malignancy.¹⁵ The decision was based largely on the known cancer risk from systemic calcineurin inhibitors in transplant patients, animal studies using very high oral doses, and a small number of spontaneous adverse event reports.

In the two decades since, the long-term human data the FDA said it was waiting for has arrived, and it overwhelmingly fails to confirm the feared risk. Dermatologists have been critical of the warning for years, arguing that it discourages appropriate use of an effective treatment and pushes patients toward prolonged topical corticosteroid use, which carries its own problems including skin thinning. The warning has not been removed, partly because the FDA moves cautiously on black box labels once applied, and partly because the cutaneous T-cell lymphoma signal, however likely it is to be confounded, has not been definitively ruled out.

For patients, the practical effect of the warning has been that pharmacists flag it, package inserts sound alarming, and some parents refuse the medication for children with eczema. A case report from 2006 describing a squamous cell carcinoma of the tongue in a patient using topical tacrolimus on oral lesions attracted attention and generated concern, but single case reports cannot establish causation, and the broader epidemiological data has not supported a skin cancer link.¹⁶

Safety Data in Children

Because atopic dermatitis is especially common in children and the black box warning specifically alarmed parents, pediatric safety data has been closely watched. A dedicated study following children who used topical tacrolimus found that over more than 44,000 person-years of follow-up, the cancer incidence was exactly what you would expect in the general population. The standardized incidence ratio was 1.01, and not a single case of lymphoma was detected.¹⁷

That result is about as reassuring as epidemiological data can be. A ratio of 1.01 means the cancer rate in treated children was virtually identical to the rate in the matched general population. The study was large enough and long enough to detect even a modest increase in risk, and it found nothing. Pediatric dermatologists generally consider topical tacrolimus a safe and valuable option for children whose eczema does not respond well to moisturizers and mild corticosteroids.

Switching Immunosuppressive Regimens After Transplant

For transplant recipients who develop cancer while on tacrolimus, one strategy is to switch part of the immunosuppressive regimen from a calcineurin inhibitor to an mTOR inhibitor like sirolimus or everolimus. These drugs suppress the immune system through a different pathway and have some anti-tumor properties of their own. In kidney transplant recipients who made this switch, the rate of new non-melanoma skin cancers dropped by roughly half, from 131 per 1,000 patient-years before the switch to 68 per 1,000 patient-years afterward.¹⁸

The approach is not without trade-offs. mTOR inhibitors have their own side effect profiles, including mouth sores, elevated cholesterol, and impaired wound healing. And the switch typically does not eliminate calcineurin inhibitors entirely; instead, tacrolimus is reduced to a lower dose while the mTOR inhibitor fills the gap. Studies of this combination approach in kidney transplant patients who developed post-transplant cancers found that rejection rates stayed low and kidney function remained stable, making it a reasonable option for the right patients.¹⁹

When Off-Label Systemic Use Enters the Picture

Tacrolimus is occasionally used systemically for autoimmune conditions other than organ transplantation, such as severe lupus or refractory inflammatory bowel disease. These situations occupy a middle ground: the doses are generally lower than full transplant-level immunosuppression, but they are still systemic. The cancer-risk data from transplant populations is the best proxy available for these patients, though the actual risk is likely lower because the exposure is typically shorter and the drug levels more modest. No large, dedicated cancer-risk studies exist for off-label systemic use, so clinicians tend to weigh the severity of the underlying disease against the theoretical risk and monitor accordingly.

Topical tacrolimus has also been studied for lupus skin lesions and other off-label dermatologic conditions. These applications share the same reassuring pharmacokinetic profile as the eczema use: the drug stays in the skin and barely reaches the blood. The limited data on these uses does not suggest any cancer concern, though the total number of patients studied remains small.

Practical Takeaways for Different Patient Groups

If you are a transplant recipient taking oral or intravenous tacrolimus, the cancer risk is real and your transplant team already factors it into your care. Keeping tacrolimus blood levels at the lowest effective target, maintaining regular cancer screening (especially skin checks), and discussing the option of mTOR inhibitor conversion if a malignancy develops are all standard parts of post-transplant management. Sun protection matters more for you than for the general population, given the outsized skin cancer risk.

If you or your child uses tacrolimus ointment for eczema, the accumulated evidence from nearly 20 years of post-marketing surveillance, large cohort studies, and meta-analyses consistently shows no meaningful increase in cancer risk. The black box warning on the label reflects a regulatory decision made in 2005 when long-term data was unavailable, and the data that has arrived since has been largely reassuring. That does not mean you should ignore the label. Discussing it with your dermatologist is reasonable. But avoiding an effective eczema treatment solely because of the warning, especially when the alternative is long-term high-potency steroid use, is a trade-off that most dermatologists would not endorse.

The gap between the transplant risk and the topical risk is enormous, driven almost entirely by the difference in how much drug enters the body. Understanding that distinction is the single most useful thing a patient can take away from this topic.